Clinical Trials Sponsored by Intercept Pharmaceuticals

Total 19673 results

Intercept Pharmaceuticals

Terminated

Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

Liver Cirrhosis, Biliary

United States, Spain, Canada, United Kingdom, France, Germany, Austria, Netherlands
Intercept Pharmaceuticals

Terminated

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT)

Liver Cirrhosis, Biliary

United States, Spain, Korea, Republic of, Australia, Finland, Israel, Lithuania, United Kingdom, Belgium, Netherlands, Estonia, Brazil, Italy, Serbia, Sweden, Argentina, Austria, Canada, Chile, Denmark, France, Germany, Hong Kong, Hun... and more
Intercept Pharmaceuticals

Terminated

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

Liver Cirrhosis, Biliary

United States, Argentina, Spain, Belgium, Germany, Canada, Australia, Estonia, Brazil, Hungary, Italy, Lithuania
Intercept Pharmaceuticals

Completed

Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) (AESOP)

Primary Sclerosing Cholangitis (PSC)

United States, Italy
Intercept Pharmaceuticals

Completed

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

Liver Cirrhosis, Biliary

United States, France, Germany, Spain, United Kingdom, Canada, Austria
Intercept Pharmaceuticals

Completed

Hepatic Impairment Trial of Obeticholic Acid

Hepatic Impairment

United States
Intercept Pharmaceuticals

Active, not recruiting

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Primary Biliary Cholangitis

Netherlands, United Kingdom, Korea, Republic of, Germany, Australia, Estonia, Belgium, France, Czechia, Croatia, Greece, Hungary, Israel, Lithuania, Norway, Poland, Spain
Intercept Pharmaceuticals

Completed

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE)

Nonalcoholic Steatohepatitis | Compensated Cirrhosis

United States, Spain, France, Australia, New Zealand, Puerto Rico, Germany, Canada, United Kingdom, Hungary, Poland, Ukraine
Intercept Pharmaceuticals

Terminated

Obeticholic Acid in Pediatric Subjects With Biliary Atresia (CARE)

Biliary Atresia

Israel, United Kingdom, Poland, Belgium, France, Germany, Italy, Netherlands, Spain
Intercept Pharmaceuticals

Completed

Effect of Food on Pharmacokinetics of Obeticholic Acid (OCA)

Healthy

United States
Intercept Pharmaceuticals

Not yet recruiting

Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy

Biliary Atresia
Intercept Pharmaceuticals

Recruiting

FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study (FRESH)

Alcohol Associated Hepatitis

United States, France, United Kingdom
Intercept Pharmaceuticals

Active, not recruiting

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Primary Biliary Cholangitis

United States
Intercept Pharmaceuticals

Terminated

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

Non Alcoholic Steatohepatitis (NASH)

United States, Finland, France, Spain, United Kingdom, Israel, Austria, Italy, Denmark, Germany, Belgium, Switzerland, Puerto Rico, Poland, Australia, Sweden, Serbia, New Zealand, Canada, Hungary, Portugal
Intercept Pharmaceuticals

Completed

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Intercept Pharmaceuticals

Completed

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis (POISE)

Primary Biliary Cirrhosis

United States, Spain, United Kingdom, Austria, Netherlands, Australia, Italy, Germany, Poland, Sweden, France, Canada, Belgium
Intercept Pharmaceuticals

Completed

Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) (CONTROL)

Nonalcoholic Steatohepatitis

United States
Intercept Pharmaceuticals

Completed

Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)

Healthy

United States
Intercept Pharmaceuticals

Completed

Study of INT-747 in Patients With Diabetes and Presumed NAFLD

Fatty Liver | Diabetes Mellitus, Type II

United States
Universitaire Ziekenhuizen KU Leuven
Intercept Pharmaceuticals

Recruiting

The Effect of Obeticholic Acid in Healthy Volunteers (OCARINA)

Healthy

Belgium
University of Milano Bicocca
Intercept Pharmaceuticals; Laboratoires Mayoly Spindler

Recruiting

National Database on Primary Biliary Cholangitis (PBC322)

Primary Biliary Cholangitis

Italy
Benedetta Terziroli, MD
Intercept Pharmaceuticals; Vifor Pharma; Fondazione Epatocentro Ticino

Completed

The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland

Primary Biliary Cirrhosis

Switzerland
Intersect ENT

Completed

A Clinical Evaluation of PROPEL® Contour Sinus Implant (EXPAND)

Chronic Rhinosinusitis (Diagnosis)

United States
Intersect ENT

Completed

A Clinical Evaluation of the Intersect ENT Sinus Device (ASCEND)

Chronic Rhinosinusitis (Diagnosis)

United States
Intersect ENT

Completed

Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint When Used Following Functional Endoscopic Sinus Surgery (FESS) in Patients With Chronic Sinusitis

Chronic Sinusitis

United States
Intersect ENT

Completed

A Clinical Evaluation of the Sinexus Intranasal Splint Following Functional Endoscopic Sinus Surgery in Patients With Chronic Rhinosinusitis (CONSENSUS II)

Chronic Sinusitis

United States
Intersect ENT

Completed

Clinical Evaluation of Propel Nova Sinus Implant in Peripheral Sinus Ostia (EXCEED)

Chronic Sinusitis

United States
Intersect ENT

Completed

Safety Evaluation of Repeat Placement of the S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps (ENCORE)

Chronic Sinusitis | Nasal Polyposis

United States
Intersect ENT

Completed

In-office Placement of the Propel Mini Sinus Implant in the Frontal Sinus Ostia (FRONTIER)

Chronic Sinusitis

United States
Intersect ENT

Completed

S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Nasal Polyps (RESOLVE_II)

Chronic Sinusitis | Nasal Polyposis

United States
Intersect ENT

Completed

Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps (RESOLVE)

Chronic Sinusitis | Nasal Polyps

United States
Intersect ENT

Completed

Safety and Performance of the Steroid-Releasing S8 Sinus Implant (S8PK)

Chronic Sinusitis

United States
Intersect ENT

Completed

A Clinical Evaluation of a Steroid-Coated Sinus Stent When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis (ADVANCE II)

Chronic Sinusitis

United States
University of Birmingham
University Hospital Birmingham NHS Foundation Trust; Intercept Pharmaceuticals

Terminated

EXerCise Intervention in cholesTatic LivEr Disease: The EXCITED Study (EXCITED)

Primary Biliary Cholangitis

United Kingdom
Intercell USA, Inc.

Completed

Traveler's Diarrhea (TD) Automated Process

Prevention of Travelers' Diarrhea

United States
Intercell USA, Inc.

Completed

Traveler's Diarrhea (TD) Vaccine Asia Efficacy Study

Traveler's Diarrhea

India, United Kingdom, Germany
Intercell USA, Inc.

Completed

ETEC Logistics Trial (TREK) (Trek)

Diarrhea

United States, Guatemala, Mexico
Intercell USA, Inc.

Completed

Prevention, Randomized, Double-Blinded, Placebo-Controlled, Parallel Assignment, Safety/Efficacy Study

Traveler's Diarrhea

United States
Intercell USA, Inc.

Completed

Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy Study

Travelers' Diarrhea

United Kingdom, Germany, Guatemala, Mexico
Intercept Pharmaceuticals
Syneos Health; Global PBC Study Group; Target RWE; UK PBC Group

Completed

Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients (HEROES PBC)

Primary Biliary Cholangitis

United States
Intercell USA, Inc.

Completed

LT Vaccine Patch Self-Administration Study

Prevention of Travelers' Diarrhea

United States
Intercell USA, Inc.

Completed

Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch

Diarrhea

United States
Intercell USA, Inc.

Completed

Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 Vaccine

Healthy

Austria, Belgium
SAMEY
Axonal-Biostatem

Unknown

A Post-Authorisation Non-Interventional Observational of Patients in France With Primary Biliary Cholangitis Treated With Obeticholic Acid in Real Life (OCARELIFE)

Primary Biliary Cholangitis

France
Intercept Pharmaceuticals
Syneos Health; Global PBC Study Group; Target RWE; UK PBC Study Group

Withdrawn

A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients (HEROES-PBC)

Primary Biliary Cholangitis

United States
Suthat Liangpunsakul
National Institute on Alcohol Abuse and Alcoholism (NIAAA); Intercept Pharmaceuticals

Completed

Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling

Alcohol Consumption

United States
Naga P. Chalasani
National Institute on Alcohol Abuse and Alcoholism (NIAAA); Intercept Pharmaceuticals

Terminated

Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH) (TREAT)

Alcoholic Hepatitis

United States
Intersect ENT
Advance Research Associates

Completed

Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus (PROGRESS)

Chronic Sinusitis

United States
Children's Fractures Interest Group, Denmark

Recruiting

Non-operative Treatment of Pediatric Lateral Humeral Condyle Fractures (NOTICE)

Fracture Humerus | Physeal Fracture

Denmark
Children's Fractures Interest Group, Denmark

Recruiting

Use of the Bioabsorbable Activa IM-Nail™ in Pediatric Diaphyseal Forearm Fractures

Child, Only | Implant Complication | Forearm Fracture | Fracture Healing | Fracture Fixation, Intramedullary

Denmark

Clinical Trials Sponsored by Intercept Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations